🔗 Share this article

Given that the United States continues making unprecedented adjustments to its immunization guidelines, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who rose to prominence by casting doubt on Covid vaccines in the pandemic and has concentrated on potential deaths following Covid vaccination in her brief position at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Vaccine Program

Health officials planned to announce sweeping changes to the childhood vaccine schedule earlier this month, aligning the US with the Danish immunization schedule, sources say – a substantial departure that would place the US out of alignment with much of the international standard with no evidence for benefit. This reveal has been postponed until the coming year.

Instead of the top vaccines chief, Høeg is listed to present at the event. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth individual to lead the center this year.

A New Direction at the FDA

This interim role could signify a closer partnership between the pharmaceutical and vaccine centers as Høeg and Prasad solidify control at the regulatory agency – and it suggests a greater focus upon dismantling already-approved immunizations at the FDA.

The new acting director has repeatedly called for ending some pediatric shot schedules in the US so as to align more similar to Denmark, a society with comprehensive healthcare and a citizenry about the population of Wisconsin’s.

In her initial statements, she has kept her attention on vaccination policy – typically the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – rather than medication approval.

Questions Over Background

Dr. Høeg has no obvious background in drug development, approval processes or management, which has been standard for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the FDA chief and CBER since March.

“She appears not to have the necessary background” for running the drug-regulation department, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a large organization. She lacks background in drug approvals.”

Previous commissioners of the center would “be deeply familiar with laws and regulations and the underlying principles of drug development”, noted Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that previous people who headed CBER have had.”

This division has an immense portfolio at the agency, Woodcock stated.

“Many people just pays attention on the novel medication approvals, but the generic drug division authorizes numerous generic medications. There is also a biologic copycat branch, over-the-counter program and so forth, and all of those must be looked after,” she explained. “The area you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a major administrative component to the job, which manages over 5,000 employees. “It is a huge leadership role, if you do it right,” the former official added.

Response and Controversial Programs

In response to concerns about Høeg’s qualifications and whether this selection represents greater collaboration among agency officials on vaccines, a press secretary said that the “concerns are based on inaccurate presumptions”.

“Her experience matches the duties of her position,” the representative explained, pointing to the period Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a contentious rapid medication authorization process that reportedly worried her predecessors. “By what process are these drugs being picked for this voucher program? Who takes the decisions?” Howard said. “There’s a lot of confidentiality happening at the regulatory body right now.”

Broadly speaking, he stated, “the Food and Drug Administration seems to be moving towards more relaxed regulations of pharmaceuticals, except for immunizations.”

Documented Past Work on Vaccines

Concerning immunizations, Høeg has a clearer, if troubling, track record, critics said. She published a analysis using unconfirmed crowd-sourced reports to determine the frequency of myocarditis after COVID-19 vaccination. She advised the state of Florida chief medical officer Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccinations are pose a greater threat than they are.

Part of her “wish list” for the incoming administration encompassed revising guidelines for new vaccines and halting “optional” immunizations, she stated following the vote on a podcast. At the FDA, Dr. Høeg has allegedly floated the idea of preventing young men from getting Covid vaccines.

“She’s an all-around dogmatist who starts off with her beliefs and reverse-engineers to retrofit the data in a highly misleading, dishonest way,” Howard said.

Consolidating Power and a “Push for Payback”

Høeg joined other dissenters, {like|